世界のジフテリア・破傷風・百日咳（DTaP）ワクチン市場予測（～2028年）：免疫DTaPワクチン、治療DTaPワクチン

• 英文タイトル：Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8790 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

ジフテリア・破傷風・百日咳（DTaP）ワクチン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のジフテリア・破傷風・百日咳（DTaP）ワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 ジフテリア・破傷風・百日咳（DTaP）ワクチン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・免疫DTaPワクチン、治療DTaPワクチン 用途別セグメントは次のように区分されます。 ・成人、小児 世界のジフテリア・破傷風・百日咳（DTaP）ワクチン市場の主要な市場プレーヤーは以下のとおりです。 ・Sanofi Pasteur、GlaxoSmithKline、Protein Sciences Corporation、Novartis AG、Seqirus、Merck Sharp & Dohme Corp、Astellas Pharma US、Pfizer Inc、Johnson & Johnson、Lanzhou Institute of Biological Products Co., Ltd、AstraZeneca、Emergent BioSolutions Inc 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、ジフテリア・破傷風・百日咳（DTaP）ワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なジフテリア・破傷風・百日咳（DTaP）ワクチンメーカーの企業概要、2019年～2022年までのジフテリア・破傷風・百日咳（DTaP）ワクチンの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なジフテリア・破傷風・百日咳（DTaP）ワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別ジフテリア・破傷風・百日咳（DTaP）ワクチンの販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までのジフテリア・破傷風・百日咳（DTaP）ワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのジフテリア・破傷風・百日咳（DTaP）ワクチン市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、およびジフテリア・破傷風・百日咳（DTaP）ワクチンの産業チェーンを掲載しています。 ・第13、14、15章では、ジフテリア・破傷風・百日咳（DTaP）ワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Sanofi Pasteur、GlaxoSmithKline、Protein Sciences Corporation、Novartis AG、Seqirus、Merck Sharp & Dohme Corp、Astellas Pharma US、Pfizer Inc、Johnson & Johnson、Lanzhou Institute of Biological Products Co., Ltd、AstraZeneca、Emergent BioSolutions Inc ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：免疫DTaPワクチン、治療DTaPワクチン ・用途別分析2017年-2028年：成人、小児 ・ジフテリア・破傷風・百日咳（DTaP）ワクチンの北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・ジフテリア・破傷風・百日咳（DTaP）ワクチンのヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・ジフテリア・破傷風・百日咳（DTaP）ワクチンのアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ジフテリア・破傷風・百日咳（DTaP）ワクチンの南米市場規模2017年-2028年：ブラジル、アルゼンチン ・ジフテリア・破傷風・百日咳（DTaP）ワクチンの中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Adult accounting for % of the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immune DTaP Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, and Seqirus, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Immune DTaP Vaccine
Therapy DTaP Vaccine
Market segment by Application can be divided into
Adult
Pediatric
The key market players for global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market are listed below:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, with price, sales, revenue and global market share of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine from 2019 to 2022.
Chapter 3, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine.
Chapter 13, 14, and 15, to describe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Immune DTaP Vaccine
1.2.3 Therapy DTaP Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Adult
1.3.3 Pediatric
1.4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size & Forecast
1.4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume (2017-2028)
1.4.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2017-2028)
1.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity Analysis
1.5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
1.6.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
1.6.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi Pasteur
2.1.1 Sanofi Pasteur Details
2.1.2 Sanofi Pasteur Major Business
2.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Protein Sciences Corporation
2.3.1 Protein Sciences Corporation Details
2.3.2 Protein Sciences Corporation Major Business
2.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Seqirus
2.5.1 Seqirus Details
2.5.2 Seqirus Major Business
2.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Merck Sharp & Dohme Corp
2.6.1 Merck Sharp & Dohme Corp Details
2.6.2 Merck Sharp & Dohme Corp Major Business
2.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Astellas Pharma US
2.7.1 Astellas Pharma US Details
2.7.2 Astellas Pharma US Major Business
2.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Pfizer Inc
2.8.1 Pfizer Inc Details
2.8.2 Pfizer Inc Major Business
2.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Johnson & Johnson
2.9.1 Johnson & Johnson Details
2.9.2 Johnson & Johnson Major Business
2.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Lanzhou Institute of Biological Products Co., Ltd
2.10.1 Lanzhou Institute of Biological Products Co., Ltd Details
2.10.2 Lanzhou Institute of Biological Products Co., Ltd Major Business
2.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 AstraZeneca
2.11.1 AstraZeneca Details
2.11.2 AstraZeneca Major Business
2.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Emergent BioSolutions Inc
2.12.1 Emergent BioSolutions Inc Details
2.12.2 Emergent BioSolutions Inc Major Business
2.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product and Services
2.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Breakdown Data by Manufacturer
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturer Market Share in 2021
3.5 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
4.1.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
4.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.5 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Type (2017-2028)
5.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Application (2017-2028)
6.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
7.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
7.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
7.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
8.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
8.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
8.3.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Region
9.3.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
10.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
10.3 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
10.3.1 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Country
11.3.1 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Production Process
12.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Distributors
13.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---